Clavis Pharma announces the cut-off level for defining hENT1 low verse high expression for assessing the results from the LEAP trial with CP-4126 in pancreatic cancer patients.
Young adulthood body weight and diet appear to be associated with the risk for non-Hodgkin lymphoma.
Appistry, Inc. announced the release of a series of advanced RNA-Seq solutions for the rapid analysis of sequencing data generated by this emerging technology.
Agilent Technologies Inc. has introduced the 709-DS Dissolution Apparatus, which features a bath-free design that provides an unobstructed view of the dissolution vessel.
Freeslate, Inc. announced that Amgen, Inc. has entered into a collaborative relationship with the company to leverage Freeslate solutions in addressing aggregation and particulation in protein drug products.
Researchers found that DFMO, or ?-difluoromethylornithine, still appeared to protect against nonmelanoma skin cancers years after people stopped taking the drug.
Biogen Idec announced positive data from the Phase 3 DEFINE clinical trial of oral BG-12 in people with relapsing-remitting multiple sclerosis.
Pharmaceutical company Pharmaxis announced the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the granting of a Marketing Authorization for Bronchitol, a cystic fibrosis treatment.
Amag Pharmaceuticals Inc. will not acquire lymphoma drug maker Allos Therapeutics Inc., as Amag's shareholders voted down the deal. Amag said its shareholders voted against issuing new stock.
Halozyme Therapeutics Inc. said that two clinical trials showed its "ultrafast" insulin worked as well as an older insulin replacement for patients with both type 1 and type 2 diabetes.
Biogen Idec and Abbott Laboratories said a mid-stage study of their multiple sclerosis medicine daclizumab showed that the experimental drug worked better than placebo at preventing relapse of symptoms of the inflammatory disease.
Researchers at UCLA have found a possible explanation for why autistic children act and think differently than their peers.
Shire announced positive results of a European Phase 3 study of once-daily lisdexamfetamine dimesylate in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.
Researchers announce findings that show the inhibition of both microRNA-33a and microRNA-33b with chemically modified anti-miR oligonucleotides suppress triglyceride levels and cause an increase in high density lipoprotein cholesterol.